Jaguar Acquisition

Jaguar Health is a commercial-stage pharmaceutical company focused on developing and commercializing plant-derived, non-opioid prescription medicines for gastrointestinal distress. The company's lead product, Mytesi (crofelemer), is the first and only oral drug approved by the FDA under botanical guidance for the symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. Jaguar is actively expanding the clinical applications of crofelemer into orphan and rare disease indications, including microvillus inclusion disease and short bowel syndrome. Through its subsidiary Napo Pharmaceuticals, the company leverages ethnobotanical research to identify and develop novel therapies sustainably derived from rainforest plants.